Previous 10 | Next 10 |
– First sickle cell patient treated with drug product manufactured with suspension-based lentiviral vector in HGB-206 – – Elivaldogene autotemcel (eli-cel, Lenti-D gene therapy) in cerebral adrenoleukodystrophy (CALD) granted accelerated assessment of Marketin...
bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord Genuity 40 th Annual Growth Conference, Wednesday, August 12, at 10:30 a.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the “Ev...
Bristol Myers Squibb (NYSE: BMY ) has resubmitted its marketing application to the FDA seeking approval of CAR T cell immunotherapy idecabtagene vicleucel (formerly bb2121) for the treatment of adults with relapsed/refractory multiple myeloma, a Breakthrough Therapy-tagged indicatio...
BLA submission based on results from pivotal Phase 2 KarMMa study evaluating ide-cel in heavily pre-treated patient population Companies are committed to working with the FDA to rapidly advance ide-cel through the regulatory review process Bristol Myers Squibb (NYSE: BMY) a...
Intellia Therapeutics (NASDAQ: NTLA) is a biotech company that focuses on gene editing, a relatively new technology that could allow scientists to devise therapies for otherwise impossible-to-treat conditions. As with any new technology, those who invest in it early enough could profit immen...
Growth stocks often trade around their all-time highs. For instance, Shopify (NYSE: SHOP) has been an expensive stock for years. And yet Shopify's stock seems to routinely double every year. Such an obvious winner is rarely cheap. Nonetheless, if you can find a wonderful growth s...
Gene-editing technology allows for the manipulation of the basic building blocks of life, so to speak. It grants scientists the ability to add, remove, or modify the genetic material of an organism, which can affect how said organism functions. Treatments based on this technology seek to replace...
Bluebird on the Go with Multiple Positive Trial Data Bluebird bio ( BLUE ) announced data from its different trials, including Phase 1/2 clinical trial for sickle cell disease and from a Phase 3 clinical trial for transfusion-dependent beta-thalassemia patients. Ongoing Phase 1/2 clinica...
Quick Take Forma Therapeutics Holdings ( FMTX ) intends to raise $200 million in an IPO of its voting common stock, per an amended registration statement. The company is developing a pipeline of drug candidates for the treatment of various hematologic (blood) diseases and cancers. FMTX...
Gene therapy company bluebird bio (NASDAQ: BLUE) gave an update on the clinical trial of its treatment for sickle cell disease (SCD) showing that patients in the study have remained free of the most serious symptoms of the disease. The results suggest that Bluebird is on track to submit the ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...